RxDoctor Payments DataLook up a doctor →

Mary Jo Hanigan, MD

Psychiatry · Omaha, NENPI 1306906326

Payments from drug & device makers

$118,782in general payments, 2019–2025

Across 1,111 payments — averaging $106.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$101K
  • AbbVie$5K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Johnson & Johnson$1K
  • Alkermes, Inc.$1K
  • Vanda Pharmaceuticals Inc.$1K
  • plus $8K from 36 others

What the payments were for

  • Speaking & faculty fees$100,54585%
  • Travel & lodging$7901%
  • Food & beverage$16,96114%
  • Education$4860%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$118,782 in reported general payments places this provider in the 95th percentile of 160 psychiatry providers in Nebraska.

See all psychiatry providers in Nebraska

Medicare billing

Part B allowed, 2024
$79,117
Medicare patients
102
Services billed
866

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate11$92,960
SunosiSolriamfetol Hcl12$11,938
Asenapine Maleate28$6,301
Bupropion XlBupropion Hcl42$1,333
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine25$761
Methylphenidate ErMethylphenidate Hcl22$721
Duloxetine Hcl12$621
Lorazepam47$597
Risperidone13$550
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine18$540
Quetiapine Fumarate44$516
Sertraline Hcl66$487
Topiramate24$455
Escitalopram Oxalate45$444
Alprazolam92$436

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$280$92,96011 claims
Axsome Therapeutics, Inc.Sunosi$737$11,93812 claims
Almatica Pharma LLCSertraline Hcl$126$48766 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 160 psychiatry providers in Nebraska.

Other psychiatry in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →